The Conversation (0)
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
Feb. 23, 2018 09:04AM PST
Life Science Investing NewsAdamas Pharmaceuticals (Nasdaq:ADMS) reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2017. As quoted in the press release: “I’m very proud of the accomplishments made by the Adamas team in 2017, especially the approval and commercial availability of GOCOVRI™, the first and only FDA-approved treatment for dyskinesia in …
Adamas Pharmaceuticals (Nasdaq:ADMS) reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2017.
As quoted in the press release:
“I’m very proud of the accomplishments made by the Adamas team in 2017, especially the approval and commercial availability of GOCOVRI™, the first and only FDA-approved treatment for dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy,” said Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive Officer of Adamas Pharmaceuticals.